ACOX3
-
Official Full Name
acyl-CoA oxidase 3, pristanoyl
-
Overview
Acyl-Coenzyme A oxidase 3 also know as pristanoyl -CoA oxidase (ACOX3)is involved in the desaturation of 2-methyl branched fatty acids in peroxisomes.Unlike the rat homolog, the human gene is expressed in very low amounts in liver such that its mRNA was undetectable by routine Northern-blot analysis or its product by immunoblotting or by enzyme activity measurements.However the human cDNA encoding a 700 amino acid protein with a peroxisomal targeting C-terminal tripeptide S-K-L was isolated and is thought to be expressed under special conditions such as specific developmental stages or in a tissue specific manner in tissues that have not yet been examined. -
Synonyms
ACOX3; acyl-CoA oxidase 3, pristanoyl; acyl Coenzyme A oxidase 3, pristanoyl; peroxisomal acyl-coenzyme A oxidase 3; Acyl-CoA oxidase, pristanoyl, peroxisomal; Acyl-Coenzyme A oxidase 3, pristanoyl; Branched-chain acyl-CoA oxidase; BRCACox; BRCOX; EST-s59; PCOX; Pristanoyl-CoA oxidase;
- Recombinant Proteins
- Protein Pre-coupled Magnetic Beads
- Human
- Mouse
- Rat
- Zebrafish
- E.coli
- HEK293
- HEK293T
- In Vitro Cell Free System
- Mammalian Cell
- Wheat Germ
- GST
- His
- His (Fc)
- Avi
- His|T7
- Myc
- DDK
- Myc|DDK
- Involved Pathway
- Protein Function
- Interacting Protein
- ACOX3 Related Articles
ACOX3 involved in several pathways and played different roles in them. We selected most pathways ACOX3 participated on our site, such as Fatty acid degradation, alpha-Linolenic acid metabolism, Biosynthesis of unsaturated fatty acids, which may be useful for your reference. Also, other proteins which involved in the same pathway with ACOX3 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Fatty acid degradation | GCDHA;ACADL;ACSL4B;HADHA;ACADM;ACAA1A;ADH1B;ACADSB;ADH4 |
alpha-Linolenic acid metabolism | PLA2G4C;ACAA1A;PLA2G2D;ACOX3;FADS2;PLA2G3;PLA2G5;PLA2G4AA;PLA2G4D |
Biosynthesis of unsaturated fatty acids | TECRB;SCD;ACOT7;Scd2;PTPLA;ACOT2;Scd1;FADS1;ELOVL6 |
Metabolic pathways | ANPEP;GBE1;ALG14;MTMR7B;FDFT1;glpK;POLG2;HSD17B2;GUSB |
Fatty acid metabolism | ACSL5;ACACA;FADS2;FASN;HSD17B12B;PECR;ACAT1;Scd2;ACAA1 |
PPAR signaling pathway | CYP8B1;ILK;SLC27A4;HMGCS2;PPARA;APOA5;FABP7;Scd2;FABP1 |
cAMP signaling pathway | GRIN3A;GHSR;FSHB;ATP1B2;GIPR;PLD1;RAP1B;NFATC1;PDE4B |
Peroxisome | CRATA;ECH1;NUDT19;PEX11G;ACSL4A;ABCD2;CRATB;AMACR;SLC25A17 |
ACOX3 has several biochemical functions, for example, acyl-CoA dehydrogenase activity, electron carrier activity, fatty-acyl-CoA binding. Some of the functions are cooperated with other proteins, some of the functions could acted by ACOX3 itself. We selected most functions ACOX3 had, and list some proteins which have the same functions with ACOX3. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
acyl-CoA dehydrogenase activity | GCDHB;GCDHA;ACADL;ACOXL;ACAD9;ACADSB;ACADM;ACADVL;ACAD8 |
electron carrier activity | IVD;CYP1A2;ACADVL;FDX1;CYP19A1;NDUFS6;CIAPIN1;CYBA;ETFDH |
fatty-acyl-CoA binding | GCDHB;ACADSB;ACOT7;ACBD4;ACBD5;ACBD3;ACBD5A;ECI2;HMGCL |
flavin adenine dinucleotide binding | ACADM;ACAD8;CYBB;GCDHA;FMO3;AOX4;TXNRD3;AOX3;MAOA |
oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor | ACAD9;GCDHB;ACOX2;ACOX3;ACADM;ACADVL;ACOX1;GCDH;ACOXL |
pristanoyl-CoA oxidase activity | ACOX3;ACOX2;ACOXL |
receptor binding | NRG4;NRXN1;AKAP9;FGF10A;ADCYAP1;CD160;REN;CTNND1;DAO1 |
ACOX3 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ACOX3 here. Most of them are supplied by our site. Hope this information will be useful for your research of ACOX3.
SMURF2; bosutinib; imatinib; dasatinib
- Q&As
- Reviews
Q&As (15)
Ask a questionACOX3 protein levels and activity have been shown to be altered in various metabolic disorders, such as X-ALD and non-alcoholic fatty liver disease (NAFLD), suggesting that it could be a potential biomarker for these conditions.
There are currently no drugs that specifically target ACOX3, but certain drugs used to treat metabolic disorders, such as bezafibrate and gemfibrozil, have been shown to stimulate the activity of ACOX3 and other fatty acid oxidation enzymes.
Mutations in the ACOX3 gene have been associated with certain peroxisomal disorders, such as X-linked adrenoleukodystrophy (X-ALD). These mutations can result in a decrease in ACOX3 activity, leading to the accumulation of VLCFAs and other metabolites that contribute to disease pathology.
ACOX3 has been used in biotechnology applications such as the production of long-chain fatty alcohols and alkanes for use as biofuels. Expression of ACOX3 can increase the production of these compounds in microbes such as E. coli.
ACOX3 expression and activity are regulated by a variety of factors, including peroxisome proliferator-activated receptor (PPAR) alpha, which is a key regulator of fatty acid oxidation. ACOX3 expression is also influenced by various signaling pathways and transcription factors, such as the sterol regulatory element-binding protein (SREBP) pathway.
There is limited research on the potential use of ACOX3 protein to improve athletic performance. While ACOX3 is involved in fatty acid oxidation, which is a major energy source for endurance exercise, further studies are needed to determine its potential as a performance-enhancing substance.
ACOX3 protein levels have been shown to be altered in certain diseases such as peroxisomal disorders, suggesting its potential as a diagnostic marker for these conditions. However, further studies are needed to determine the diagnostic utility of ACOX3 in clinical settings.
ACOX3 has been identified as a potential therapeutic target for metabolic disorders, particularly X-ALD. However, further research is needed to develop targeted therapies.
ACOX3 works in concert with other enzymes involved in fatty acid metabolism, including carnitine palmitoyltransferase (CPT) and acyl-CoA dehydrogenase (ACAD). CPT transfers fatty acids into the mitochondria for oxidation, while ACAD is responsible for the initial step in beta-oxidation.
Certain dietary interventions, such as fasting and the consumption of medium-chain triglycerides (MCTs), have been shown to increase ACOX3 activity and fatty acid oxidation in the liver.
In addition to its role in the oxidation of VLCFAs, ACOX3 has also been shown to play a role in the synthesis of certain lipids, such as sphingolipids and plasmalogens. These lipids have important functions in cellular membranes and signaling pathways.
The role of ACOX3 in cancer development is not well understood. Some studies have suggested that ACOX3 expression is decreased in certain types of cancer, such as bladder cancer, while others have shown increased expression in breast cancer. More research is needed to determine the potential role of ACOX3 in cancer development and progression.
ACOX3 has been suggested as a potential target for drug development in a variety of metabolic disorders, including peroxisomal disorders and nonalcoholic fatty liver disease (NAFLD). Inhibition of ACOX3 activity has been shown to reduce the accumulation of VLCFA, which can contribute to disease pathology.
ACOX3 expression has been shown to be altered in certain metabolic disorders such as peroxisomal disorders and NAFLD, suggesting its potential as a biomarker for these conditions. However, further studies are needed to determine its diagnostic utility in clinical settings.
Various techniques are used to study ACOX3 protein, including Western blotting, immunohistochemistry, and mass spectrometry. In addition, genetic manipulation of cells and animal models can be used to investigate the physiological functions and regulation of ACOX3.
Ask a Question for All ACOX3 Products
Required fields are marked with *
My Review for All ACOX3 Products
Required fields are marked with *